Sarcoma
PRINCIPAL INVESTIGATORS
- Xavier Garcia del Muro Solans
CLINICAL RESEARCHERS
- Francesc Xavier Sanjuan Garriga
- Juan Jesus Martin Liberal
POSTDOCTORAL RESEARCHERS (R2)
- Mariona Chicón Bosch
- Laura Santana Viera
PREDOCTORAL RESEARCHERS (R1)
- Paola Monaco
- Sara Sanchez Serra
SCIENTIFIC SUPPORT
- Roser Lopez Alemany
- Susana Maqueda Marcos
Cancer
Oncobell
Scientific production
12
PAPERS
Impact factor: 151,266
4 PUBLICATIONS IN FIRST DECILE
7 PUBLICATIONS IN FIRST QUARTILE
Selected publications
- Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström AC; Grande E. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. LANCET. 10.1016/S0140-6736(20)30230-0
- Petrylak, Daniel P.; de Wit, Ronald; Chi, Kim N.; Drakaki, Alexandra; Sternberg, Cora N.; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed A.; Flechon, Aude; Bamias, Aristotelis; Yu, Evan Y.; van der Heijden, Michiel S.; Matsubara, Nobuaki; Alekseev, Boris; Necchi, Andrea; Geczi, Lajos; Ou, Yen-Chuan; Coskun, Hasan Senol; Su, Wen-Pin; Bedke, Jens; Gakis, Georgios; Percent, Ivor J.; Lee, Jae-Lyun; Tucci, Marcello; Semenov, Andrey; Laestadius, Fredrik; Peer, Avivit; Tortora, Giampaolo; Safina, Sufia; Garcia del Muro, Xavier; Rodriguez-Vida, Alejo; Cicin, Irfan; Harputluoglu, Hakan; Tagawa, Scott T.; Vaishampayan, Ulka; Aragon-Ching, Jeanny B.; Hamid, Oday; Liepa, Astra M.; Wijayawardana, Sameera; Russo, Francesca; Walgren, Richard A.; Zimmermann, Annamaria H.; Hozak, Rebecca R.; Bell-McGuinn, Katherine M.; Powles, Thomas. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. LANCET ONCOLOGY. 10.1016/S1470-2045(19)30668-0
- Sanchez-Molina, Sara; Figuerola-Bou, Elisabet; Blanco, Enrique; Sanchez-Jimenez, Maria; Taboas, Pablo; Gomez, Soledad; Ballare, Cecilia; Garcia-Dominguez, Daniel J.; Prada, Estela; Hontecillas-Prieto, Lourdes; Carcaboso, Angel M.; Tirado, Oscar M.; Hernandez-Munoz, Inmaculada; de Alava, Enrique; Lavarino, Cinzia; Di Croce, Luciano; Mora, Jaume. RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis. SCIENCE ADVANCES. 10.1126/sciadv.aba3058
- Sanz-Pamplona, Rebeca; Melas, Marilena; Maoz, Asaf; Schmit, Stephanie L.; Rennert, Hedy; Lejbkowicz, Flavio; Greenson, Joel K.; Sanjuan, Xavier; Lopez-Zambrano, Maria; Henar Alonso, M.; Qu, Chenxu; McDonnell, Kevin J.; Idos, Gregory E.; Vignali, Marissa; Emerson, Ryan; Fields, Paul; Guino, Elisabet; Santos, Cristina; Salazar, Ramon; Robins, Harlan S.; Rennert, Gad; Gruber, Stephen B.; Moreno, Victor. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis. PLOS MEDICINE. 10.1371/journal.pmed.1003292
- Almacellas-Rabaiget, Olga; Monaco, Paola; Huertas-Martinez, Juan; Garcia-Monclus, Silvia; Chicon-Bosch, Mariona; Maqueda-Marcos, Susana; Fabra-Heredia, Isabel; Herrero-Martin, David; Rello-Varona, Santiago; de Alava, Enrique; Lopez-Alemany, Roser; Giangrande, Paloma H.; Tirado, Oscar M.. LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity. CANCER LETTERS. 10.1016/j.canlet.2019.12.040
Research highlights
PROJECTS
9 Ongoing projects
2 Granted projects
43 Ongoing clinical trials
13 Started clinical trial
PUBLISHED WORKS
2 Ongoing theses
INNOVATION
1 Patent
1 License
1 Spin off
Selected projects
- Ensayo de fase 3, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de Pembrolizumab (MK-3475) y Lenvatinib (E7080/MK-7902) en comparación con Pembrolizumab en monoterapia como intervención de primera línea en participantes con melanoma avanzado (LEAP-003) (2019 – 2024) PI: MARTIN LIBERAL, JUAN JESUS. Funder ref.: MK-7902-003.
- Molecular analysis of the metastatic process in developmental tumors (2020 – 2023) PI: MARTINEZ TIRADO, OSCAR. Funder: FUNDACIO LA MARATO DE TV3.
- Estudio de fase I, abierto, multicéntrico y de varis grupos de MK-1308 en combinación con Pembrolizumab en sujetos con tumores sólidos avanzados (2020 – 2020) PI: MARTIN LIBERAL, JUAN JESUS. Funder ref.: MK-1308-001.
- Estudio de fase 1B/2 DE LY3200882 y Pembrolizumab en pacientes con cáncer avanzado (2019 – 2020) PI: MARTIN LIBERAL, JUAN JESUS. Funder ref.: I8X-MC-JECD.
- Phase 1-2 study investigating safty, tolerability, pharmacokinetics and preliminary antitumor activity of anti-PD-L1 monoclonal antibody BGB-A333 alone and in combination with anti-PD-1 monoclonal antibody Tislelizumab in patients with advanced solid tumors (2019 – 2020) PI: MARTIN LIBERAL, JUAN JESUS. Funder ref.: BGB-900-101.